title: Trabectedin in the neoadjuvant treatment of high-grade pleomorphic sarcoma: report of a rare case and literature review.
abstract: Background. Pleomorphic sarcoma is an aggressive soft tissue sarcoma. In patients with high-risk extremity sarcomas, the significant survival benefits conferred by an intense regimen of neoadjuvant chemoradiotherapy and surgery were reported. To our knowledge, this is the first report in the literature of the neoadjuvant use of trabectedin in a patient with high-grade pleomorphic sarcoma, ineligible for standard neoadjuvant combination therapy with an anthracycline-based regimen. Case Presentation. Here we present a 58-year-old White male with a large tumor in the left thigh, but with no signs of metastases. Owing to the history of severe heart attack, three cycles of neoadjuvant trabectedin were administrated to achieve surgically wide margins. After two cycles, an 18F-FDG-PET showed a large proportion of the central tumor area was without metabolic activity. According to RECIST and Choi criteria, the tumor was stable. After the third cycle of trabectedin, the patient underwent a complete resection, which revealed completely necrotic high-grade pleomorphic sarcoma (stage pT2b), with only a small vital area. Conclusion. The present paper on a promising treatment with neoadjuvant trabectedin of patients with high-grade pleomorphic sarcoma might suggest that such treatment approach may provide a greater chance of cure and survival of such patients.
authors: Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, 01307 Dresden, Germany.
authors: Markus K
authors: MK
authors: Schuler
authors: Stephan
authors: S
authors: Richter
authors: Ivan
authors: I
authors: Platzek
authors: Bettina
authors: B
authors: Beuthien-Baumann
authors: Kathrin
authors: K
authors: Wieczorek
authors: Christine
authors: C
authors: Hamann
authors: Johannes
authors: J
authors: Mohm
authors: Gerhard
authors: G
authors: Ehninger
references: Drugs. 2010 Feb 12;70(3):355-76
references: 20166769
references: J Clin Oncol. 2005 Aug 20;23(24):5484-92
references: 16110008
references: Cancer Res. 2005 Apr 1;65(7):2964-71
references: 15805300
references: J Clin Oncol. 2004 Mar 1;22(5):890-9
references: 14990645
references: Clin Cancer Res. 2012 Apr 1;18(7):2024-31
references: 22338012
references: Ann Oncol. 2010 Dec;21(12):2436-2441
references: 20439343
references: J Clin Oncol. 2005 Jan 20;23(3):576-84
references: 15659504
references: Lancet Oncol. 2007 Jul;8(7):595-602
references: 17586092
references: Mol Cancer Ther. 2010 Aug;9(8):2157-63
references: 20647340
references: Ann Oncol. 2010 May;21 Suppl 5:v198-203
references: 20555081
references: J Clin Oncol. 2009 Sep 1;27(25):4188-96
references: 19652065
references: Cancer. 2012 Dec 1;118(23):5857-66
references: 22605504
references: Ann Oncol. 2011 Jun;22(6):1266-1272
references: 21183581
references: Cancer Res. 2010 Mar 15;70(6):2235-44
references: 20215499
references: Ann Oncol. 2009 Aug;20(8):1439-44
references: 19465423
references: Cancer. 2012 Aug 1;118(15):3758-65
references: 22180344
references: Ann Oncol. 2012 Sep;23 Suppl 10:x167-9
references: 22987955
references: Ann Oncol. 2012 Mar;23(3):771-776
references: 21642514
references: Curr Opin Oncol. 2010 Jul;22(4):342-6
references: 20489618
references: Cancer. 2010 Oct 1;116(19):4613-21
references: 20572040